What Is Ozempic-Induced Gastroparesis?
Gastroparesis means "stomach paralysis" — a condition where the stomach muscles cannot contract normally to move food through the digestive system. GLP-1 drugs like Ozempic work by dramatically slowing gastric emptying, and in a significant subset of patients this slowing becomes pathological. The result is severe, persistent nausea, vomiting of undigested food, abdominal pain, bloating, and malnutrition.
The Failure-to-Warn Argument
Before January 2025, Ozempic's label did not mention gastroparesis by name. The label described common GI side effects like nausea and vomiting but did not warn that these could represent the onset of a serious, potentially permanent condition. Plaintiffs argue that Novo Nordisk knew or should have known about the gastroparesis risk from clinical trial data showing 82.2% GI adverse event rates.
Is Ozempic Gastroparesis Permanent?
In some patients, gastroparesis resolves after stopping the drug. In others, it persists for months or years. Some patients develop permanent gastroparesis requiring ongoing medical management, tube feeding, or surgical intervention such as gastric electrical stimulator implantation.
The Gastric Emptying Study Requirement
An August 2025 MDL ruling requires gastroparesis plaintiffs to have a properly performed gastric emptying scintigraphy study confirming delayed gastric emptying at the time of diagnosis. If you are experiencing gastroparesis symptoms, obtaining this diagnostic study is critical for both your medical care and any potential legal claim.
Scientific Evidence
Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway JT, Shah MP, Hathaway DB, et al. (2024). JAMA Ophthalmology
Key Findings
- Type 2 diabetes patients: 8.9% NAION risk on semaglutide vs 1.8% on non-semaglutide medications
- Weight-loss patients: 6.7% NAION risk vs 0.8% on alternatives
- Risk was highest in first year of use
- Findings confirmed by Danish/Norwegian cohort study of 424,000+ patients
- EMA required European label update; Novo Nordisk has not updated U.S. labels
Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss
Sodhi M, Rezaeianzadeh R, Kezouh A, Bhatt M (2023). JAMA
Key Findings
- Gastroparesis hazard ratio: 3.67 (95% CI 1.15-11.90)
- Bowel obstruction hazard ratio: 4.22 (95% CI 1.02-17.40)
- Pancreatitis hazard ratio: 9.09 (95% CI 1.25-66.00)
- Study population was non-diabetic weight-loss patients — directly relevant to majority of MDL plaintiffs
- Findings were robust across sensitivity analyses
GLP-1 Receptor Agonists and Gallbladder Disease: A Systematic Review of Randomized Controlled Trials
Multiple authors (systematic review) (2024). Clinical Gastroenterology and Hepatology
Key Findings
- 37% increased relative risk of gallbladder disease across 76 RCTs
- Risk was more pronounced with higher doses and greater weight loss
- Rapid weight loss mechanism contributes to gallstone formation
- Risk increased with duration of GLP-1 agonist use
- Findings support inclusion of gallbladder disease in GLP-1 litigation claims
Frequently Asked Questions
Related Pages
Ozempic Gallbladder Problems
GLP-1 drug users face a 37% increased risk of gallbladder disease. Rapid weight loss combined with GLP-1 effects on bile duct motility creates conditions for gallstone formation and cholecystitis.
Ozempic Pancreatitis Lawsuit
The JAMA 2023 study found a 9.09x increased risk of pancreatitis among GLP-1 users for weight loss. Acute pancreatitis can be life-threatening and requires hospitalization.
Ozempic Bowel Obstruction
GLP-1 drugs slow motility throughout the entire GI tract, not just the stomach. Severe slowing can cause ileus or mechanical bowel obstruction — life-threatening emergencies that may require surgery.
Ozempic Vision Loss (NAION)
Studies show semaglutide users face 4-8x higher risk of NAION — sudden, painless, permanent vision loss. The EMA required European warnings in 2024, but U.S. labels still do not include a NAION warning.
Ozempic Settlement Amounts
No GLP-1 trials have concluded yet, but projected settlements based on comparable pharmaceutical mass torts suggest $100,000 to $1.5 million+ depending on injury severity.
Novo Nordisk GLP-1 Lawsuit
Novo Nordisk generated $29.3 billion in semaglutide revenue in 2024 while allegedly failing to warn about severe side effects. The company's aggressive marketing and delayed label updates are central to the litigation.
Ozempic, Wegovy & Mounjaro Lawsuits
The GLP-1 MDL consolidates claims against both Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). All semaglutide and tirzepatide products are at issue.
Ozempic Vision Loss (NAION) Lawsuit
A growing body of evidence links GLP-1 receptor agonist medications — including Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) — to non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of blood flow to the optic nerve that can cause permanent vision loss. A landmark Harvard/Mass Eye and Ear study published in 2024 found GLP-1 users face significantly elevated NAION risk. In December 2025, a second federal MDL was established specifically for NAION vision loss claims, separate from the existing gastroparesis MDL. As of late 2025, nearly 2,947 lawsuits have been filed by patients alleging vision damage. The first bellwether trials are scheduled for early 2026. If you experienced sudden vision loss, blurred vision, or were diagnosed with NAION while taking Ozempic, Wegovy, or Mounjaro, consult an attorney immediately.
Learn moreOzempic / GLP-1 Lawsuits Lawsuit
GLP-1 receptor agonist drugs — including Novo Nordisk's Ozempic, Wegovy, and Rybelsus, and Eli Lilly's Mounjaro and Zepbound — have generated over $40 billion in annual sales while allegedly causing severe gastrointestinal injuries that manufacturers failed to adequately disclose. Over 3,100 lawsuits are consolidated in MDL 3094 in the Eastern District of Pennsylvania, with a separate NAION vision-loss MDL (3163) established in December 2025.
View full case overview